-
COST-EFFECTIVENESS OF TRIFLURIDINE/TIPIRACIL PLUS BEVACIZUMAB VERSUS REGORAFENIB IN REFRACTORY METASTATIC COLORECTAL CANCER IN KAZAKHSTAN
Mar 18, 2026, 21:38 PM -
ESTIMATING MEANINGFUL CHANGE THRESHOLDS (MCTS) FOR EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC) SCALES IN A PHASE 3 TRIAL FOR PATIENTS WITH LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)
Mar 18, 2026, 21:38 PM -
EVALUATING AI MODELS FOR DRUG PRICING ANALYTICS: A COMPARATIVE STUDY FOR MOST-FAVORED-NATION POLICY MODELING
Mar 18, 2026, 21:38 PM -
DOES SUBSTANDARD CANCER CARE ADVERSELY IMPACT PATIENT FINANCIAL WELL BEING? AN ANALYSIS OF CANCER REGISTRY, CLAIMS, AND CREDIT REPORT SCORES
Mar 18, 2026, 21:38 PM -
STRUCTURED EXPERT ELICITATION IN GLOBAL HTAS: ACCEPTANCE AND APPLICATION
Mar 18, 2026, 21:38 PM -
REAL WORLD TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG PATIENTS WITH ASTHMA RECEIVING BIOLOGIC THERAPY: A TARGETED LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
THE NEED TO CONSIDER THE IMPACT OF DRIVERS OF RELATIVE TREATMENT EFFECTS BEYOND TREATMENT CHOICE IN COST-EFFECTIVENESS ANALYSES (CEA)
Mar 18, 2026, 21:38 PM -
EXPERT CONSENSUS ON TREATMENT GUIDANCE FOR FDA-APPROVED AND SECOND-GENERATION EXON-SKIPPING THERAPIES IN DUCHENE MUSCULAR DYSTROPHY (DMD): A RAND/UCLA MODIFIED DELPHI PANEL
Mar 18, 2026, 21:38 PM -
INCIDENCE OF IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED PNEUMONITIS AMONG NON-SMALL CELL LUNG CANCER PATIENTS WITH AND WITHOUT PRE-EXISTING COPD
Mar 18, 2026, 21:38 PM -
SELF-REPORTED MARIJUANA USE, PAIN LEVELS, AND OPIOID USE AMONG ADULT CANCER SURVIVORS IN ARKANSAS
Mar 18, 2026, 21:38 PM -
PREFERENCES FOR ADOPTING A MOBILE HEALTH APP: A BEST-WORST SCALING AND DISCRETE CHOICE EXPERIMENT
Mar 18, 2026, 21:38 PM -
CLINICAL AND HUMANISTIC BURDEN OF ADULT PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 WITH PLEXIFORM NEUROFIBROMA IN THE REAL-WORLD SETTING ACROSS FOUR EUROPEAN COUNTRIES: RESULTS FROM A REAL-WORLD SURVEY
Mar 18, 2026, 21:38 PM -
A NOVEL APPROACH FOR GENERATING ROBUST POPULATION ESTIMATES FOR USE IN HTA AND REGULATORY SUBMISSIONS: DEMONSTRATION IN CLL IN GERMANY
Mar 18, 2026, 21:38 PM -
THE IMPACT OF CARING FOR THEIR CHILDREN WITH RETT SYNDROME: A MULTI-METHOD STUDY
Mar 18, 2026, 21:38 PM -
REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AND ECONOMIC BURDEN OF NARCOLEPSY TYPE 1 IN THE US
Mar 18, 2026, 21:38 PM -
ALIGNING INNOVATION, IMPLEMENTATION, PATIENT VOICE, INSTITUTIONAL TIMELINES, AND CONTINUITY IN UHC-ALIGNED POPULATION SCREENING
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS OF SAVOLITINIB-OSIMERTINIB IN ADVANCED NON-SQUAMOUS NSCLC WITH MET AMPLIFICATION FOLLOWING EGFR-TKI RESISTANCE IN CHINA
Mar 18, 2026, 21:38 PM -
A MULTI-MODEL LARGE LANGUAGE FRAMEWORK FOR AUTOMATING SYSTEMATIC LITERATURE REVIEWS
Mar 18, 2026, 21:38 PM -
RAPIDLY EVOLVING TREATMENT LANDSCAPE IN MULTIPLE MYELOMA - LEVERAGING A LIVING SYSTEMATIC LITERATURE REVIEW (SLR)
Mar 18, 2026, 21:38 PM -
EXTENSION OF AGENT BASED MODELING IN CHINA’S NATIONAL VOLUME BASED DRUG PROCUREMENT: BIDDING SIMULATION AND POLICY IMPLICATIONS
Mar 18, 2026, 21:38 PM
